INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

GlobeNewsWire • 10 hours ago

Zevra Therapeutics Q2 Earnings Call Highlights

Zevra Therapeutics NASDAQ: ZVRA reported second-quarter 2026 net revenue of $39.7 million, up 53% from $25.9 million a year earlier, driven primarily by U.S. sales of its Niemann-Pick disease type C treatment MIPLYFFA.

MarketBeat • Aug 6, 2026

Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript

Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position of $260.2 million Company to host conference call and webcast TODAY, August 5, 2026 , at 4:30 p.m. ET BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today reported its financial results for the second quarter ended June 30, 2026.

GlobeNewsWire • Aug 5, 2026

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $1.21 per share a year ago.

Zacks Investment Research • Aug 6, 2026

Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra's executive leadership team will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 11:00 a.m. ET. Additionally, management will be available for one-on-one meetings with registered conference attendees.

GlobeNewsWire • Aug 4, 2026

Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky

Zevra investors who relied on public statements about arimoclomol's approval status faced losses after the July 24, 2026 negative opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use ("CHMP"). NEW YORK, Aug. 3, 2026 /PRNewswire/ -- On July 24, 2026, Zevra Therapeutics (NASDAQ: ZVRA) shares fell approximately 24% after the European Medicines Agency's CHMP issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for Niemann-Pick disease type C.

PRNewsWire • Aug 3, 2026

Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)

Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient population Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient population

GlobeNewsWire • Aug 3, 2026

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Zevra Therapeutics (ZVRA)

Zevra Therapeutics investors saw shares fall after European regulators issued a negative opinion on arimoclomol. The investigation focuses on Zevra's regulatory statements and the July 24, 2026 CHMP decision. Zevra Therapeutics investors saw shares fall after European regulators issued a negative opinion on arimoclomol. The investigation focuses on Zevra's regulatory statements and the July 24, 2026 CHMP decision.

GlobeNewsWire • Jul 30, 2026

ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)

NEW YORK--(BUSINESS WIRE)--On July 24, 2026, Zevra Therapeutics (NASDAQ: ZVRA) shares fell approximately 24% after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for Niemann-Pick disease type C. Investors who suffered losses tied to the ZVRA drop are encouraged to submit your loss information now or contact Levi & Korsinsky, LLP | (212) 363-7500 | www.zlk.c.

Business Wire • Jul 29, 2026